Research Article
The Association of the Immune Response Genes to Human Papillomavirus-Related Cervical Disease in a Brazilian Population
Table 3
Distribution of KIR and HLA ligands in HPV patients and controls.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bw4: HLA-A*23, 24, and 32; HLA-B*08, 13, 27, 37, 44, 51, 52, 53, 57, and 58. Group C1: HLA-C*01, 03, 07, 08, 12, 14, and 16. Group C2: HLA-C*02, 04, 05, 06, 07, 15, 17, and 18. Difference was not observed (). |